Cargando…
Identification of actionable targets for breast cancer intervention using a diversity outbred mouse model
HER2-targeted therapy has improved breast cancer survival, but treatment resistance and disease prevention remain major challenges. Genes that enable HER2/Neu oncogenesis are the next intervention targets. A bioinformatics discovery platform of HER2/Neu-expressing Diversity Outbred (DO) F1 Mice was...
Autores principales: | Jacob, Jennifer B., Wei, Kuang-Chung, Bepler, Gerold, Reyes, Joyce D., Cani, Andi, Polin, Lisa, White, Kathryn, Kim, Seongho, Viola, Nerissa, McGrath, Julie, Guastella, Anthony, Yin, CongCong, Mi, Qing-Shen, Kidder, Benjamin L., Wagner, Kay-Uwe, Ratner, Stuart, Phillips, Victoria, Xiu, Joanne, Parajuli, Prahlad, Wei, Wei-Zen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034465/ https://www.ncbi.nlm.nih.gov/pubmed/36968078 http://dx.doi.org/10.1016/j.isci.2023.106320 |
Ejemplares similares
-
Implications of the USP10-HDAC6 axis in lung cancer - A path to precision medicine
por: Zhang, Xiaohong Mary, et al.
Publicado: (2016) -
A Method for Biomarker Directed Survival Prediction in Advanced Non-Small-Cell Lung Cancer Patients Treated with Carboplatin-Based Therapy
por: Chen, Wei, et al.
Publicado: (2013) -
qtl.outbred: Interfacing outbred line cross data with the R/qtl mapping software
por: Nelson, Ronald M, et al.
Publicado: (2011) -
Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer
por: McKnight, Brooke N., et al.
Publicado: (2020) -
The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53
por: Hu, Chen, et al.
Publicado: (2020)